GLP-1 diet study: what happens when you eat on ozempic?

NCT ID NCT07001553

Completed Knowledge-focused Sponsor: Australian Catholic University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how people change their eating habits after starting GLP-1 drugs like Ozempic or Mounjaro for weight or diabetes. Researchers tracked 37 adults using dietary records and questionnaires to see if it's feasible to study diet changes this way. The goal was to understand recruitment and retention, not to test the drugs themselves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 agonist (e.g., Ozempic, Trulicity, Mounjaro, Saxenda)
What this could lead to: If successful, this could help doctors understand how diet changes with these medications, leading to better dietary advice for patients.
What could go wrong: This is a small, completed feasibility study with only 37 participants, so results may not apply broadly. It only observed dietary patterns, not treatment effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Show contact details

Locations

Australian Catholic University

Fitzroy, Victoria, 3065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.